The ACTR1B Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 769-P renal cell carcinoma line. This product comprises a heterogeneous pool of cells in which the ACTR1B gene has been disrupted via CRISPR/Cas9-mediated gene editing, yielding a loss-of-function model for studies of dynactin complex biology. The polyclonal format preserves genetic diversity while enabling robust functional interrogation of ACTR1B-dependent processes, making it suitable for applications where clonal homogeneity is not required.
The 769-P host cell line was originally established from a primary clear cell renal cell carcinoma and retains key characteristics of the renal tubular epithelium. As an adherent epithelial kidney cancer cell line, 769-P provides a physiologically relevant background for analyzing oncogenic signaling and cytoskeletal dynamics in the context of renal cancer. Its well-documented behavior in standard culture conditions and extensive literature support make it a robust platform for gene knockout studies.
ACTR1B encodes actin-related protein 1B, an essential subunit of the dynactin complex that functions as a cofactor for cytoplasmic dynein. The dynactin complex, comprising multiple subunits including DCTN1/p150Glued, DCTN2/p50/dynamitin, DCTN3, and DCTN4, cooperates with dynein heavy chain (DYNC1H1) and intermediate chains to facilitate minus-end-directed transport along microtubules. ACTR1B is critical for dynactin integrity and participates in linking cargoes to the dynein motor, thereby regulating processes such as organelle trafficking, mitotic spindle orientation, and microtubule anchorage at centrosomes. Its activity is influenced by cell cycle-dependent expression and microtubule dynamics, positioning ACTR1B as a central node in cytoskeleton organization and intracellular transport.
Disruption of ACTR1B in 769-P cells is expected to impair dynactin assembly and dynein-mediated retrograde transport, leading to alterations in microtubule organization and cargo distribution. Given the role of dynactin in cell division and motility, this knockout model allows exploration of how cytoskeletal dysregulation contributes to renal cell carcinoma progression. The 769-P background is particularly relevant for studying the interplay between aberrant transport mechanisms and cancer cell phenotypes, including invasion and drug resistance.
This knockout cell population is suitable for a range of experimental approaches, including Western blotting to assess dynactin subunit expression, immunofluorescence analysis of microtubule and dynactin localization, and live-cell imaging of organelle transport dynamics. Functional assays such as cell migration, invasion, and drug sensitivity testing can be used to evaluate the impact of ACTR1B loss on cancer cell behavior. Co-immunoprecipitation studies enable examination of residual dynactin complex assembly in the absence of ACTR1B. Additionally, the model serves as a tool for investigating dynactinopathies related to hereditary spastic paraplegia, Perry syndrome, and amyotrophic lateral sclerosis. For further details, please contact Ascent Research.
